A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Nov 2023 Results assessing transcriptomic profile of SLE patients who were responsive to baricitinib and the impact of the agent on gene expression abnormalities, presented at the ACR Convergence 2023
04 Jun 2022 Results of a pooled safety analysis from three clinical studies: NCT02708095, NCT03616912 and NCT03616964 presented at the 23rd Annual Congress of the European League Against Rheumatism
24 May 2022 Results published in the Annals of the Rheumatic Diseases

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com